New International Bureau for Epilepy Survey Highlights 'What Really Matters' to People With Epilepsy Today

ENDS *** Notes to Editors About the IBE The International Bureau for Epilepsy (IBE) is a worldwide umbrella organisation, with a powerful global network of 122 members in 92 countries, providing a platform for the representation of epilepsy and promoting understanding and knowledge of the condition. IBE Members are lay organizations, with membership accessible to all. Members are grouped regionally, in line with the regional boundaries adopted by the WHO, so that every member of IBE is also a member of a Regional Committee. 50 years focused on epilepsy Created in 1961, this year marks the 50th anniversary of the IBE and the Golden Jubilee of its foundation. Throughout the past five decades, the IBE has focused on improving epilepsy care and remains committed to finding new and innovative solutions to the problems impacting people with epilepsy and their families world-wide. For further information please visit the IBE's web site http://www.ibe-epilepsy.org Eisai in epilepsy Eisai is committed to developing and delivering highly beneficial new treatments to help improve the lives of people with epilepsy. The development of anti-epileptic drugs (AEDs) is a major strategic area for Eisai. About Eisai Eisai is one of the world's leading R&D-based pharmaceutical companies and has defined its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc). Eisai concentrates its R&D activities in three key areas: neuroscience; oncology and vascular / immunological reaction. With operations in the U.S., Asia, Europe and its domestic home market of Japan, we employ more than 11,000 people worldwide. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Hungary, Slovakia and the Netherlands. For further information please visit Eisai's web site http://www.eisai.com Rückfragehinweis: Media contacts, Eisai Europe Ltd, Cressida Robson (+44-7908-314-155 / [email protected]), Tonic Life Communications, Helen Swift / Benjamyn Tan (+44 774 7111217 / +44 7792 034 191), [email protected], [email protected], International Bureau For Epilepsy, Ann Little (+353 1210 8850 / [email protected]) Digitale Pressemappe: http://www.ots.at/pressemappe/PR102413/aom *** OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | PRN

print